| アイテムタイプ |
itemtype_ver1(1) |
| 公開日 |
2025-11-28 |
| タイトル |
|
|
タイトル |
Post-transplant TKIs for Ph plus ALL: practices to date and clinical significance |
|
言語 |
en |
| 著者 |
Nishiwaki, Satoshi
Terakura, Seitaro
Morishita, Takanobu
Goto, Tatsunori
Inagaki, Yuichiro
Miyao, Kotaro
Fukushima, Nobuaki
Hirano, Daiki
Tange, Naoyuki
Kurahashi, Shingo
Kuwatsuka, Yachiyo
Kasai, Masanobu
Iida, Hiroatsu
Ozeki, Kazutaka
Sawa, Masashi
Nishida, Tetsuya
Kiyoi, Hitoshi
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利 |
|
|
権利情報 |
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s12185-025-03917-1 |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Post-transplant tyrosine kinase inhibitors (TKIs) show promise in preventing relapse after allogeneic hematopoietic cell transplantation (allo-HCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). However, their real-world use and efficacy remain unclear. A comprehensive study across seven centers included Ph+ALL patients who underwent allo-HCT between 2002 and 2022. Post-transplant TKIs were administered in 28% of patients (49 of 173 transplanted in complete remission): 7% as prophylaxis during complete molecular remission (CMR), and 21% in response to measurable residual disease (MRD) positivity. Median first post-transplant TKI duration was 13.7 months for the prophylactic group and 4.0 months for the MRD-triggered group. Prophylactic TKIs appear particularly beneficial for patients not in CMR at allo-HCT, showing a trend towards higher 5-year relapse-free survival (RFS) compared to those not receiving prophylactic TKIs (100% vs. 73%; P = 0.11). Significant RFS differences were observed between the prophylactic, non-TKI, and MRD-triggered groups. However, patients with white blood cell counts <15000/µl at diagnosis and no additional chromosomal abnormalities—an MRD-triggered high efficacy cluster—demonstrated comparable 5-year RFS regardless of TKI strategy (100% vs. 85% vs. 80%; P = 0.87). This cluster highlights the potential effectiveness of MRD-triggered TKI administration in select low-risk patients, suggesting tailored TKI strategies based on risk factors. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Springer |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプresource |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1007/s12185-025-03917-1 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0925-5710 |
| 書誌情報 |
en : INTERNATIONAL JOURNAL OF HEMATOLOGY
巻 121,
号 4,
p. 494-503,
発行日 2025-04
|
| ファイル公開日 |
|
|
日付 |
2026-04-01 |
|
日付タイプ |
Available |
IJHM-D-24-00625_R2finalversion.pdf (787 KB)
